We can’t show the full text here under this license. Use the link below to read it at the source.
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Combined activation of brain GIP and GLP-1 receptors helps reduce weight in obese mice
AI simplified
Abstract
A peptide-antibody conjugate that blocks while activating is essential for maximal weight loss in obese mice.
- CNS GIPR and GLP-1R are both necessary for achieving the full weight loss benefits of the GIPR-Ab/GLP-1 treatment.
- Dulaglutide leads to greater weight loss in mice lacking CNS GIPR compared to those with it.
- The combination of dulaglutide and GIPR-Ab results in reduced weight loss in CNS GIPR knockout mice.
- Mice treated with GIPR-Ab/GLP-1 and CNS GIPR knockout mice show similar changes in gene expression related to fat tissue and liver function.
- Activation of specific brain regions related to appetite regulation occurs with the GIPR-Ab/GLP-1 treatment.
AI simplified
Key numbers
31.9%
Weight Loss Percentage
Average weight loss observed by day 18 in treated mice.
19.4%
Body Weight Change in Female Mice
Percentage weight loss in female mice treated with .